Dolcil 2 mg, 30 tablets

Trade name:

Dolcil

Dolcyl

Properties

Hypoglycemic drug for oral administration — a third generation sulfonylurea derivative.

Glimepiride acts primarily by stimulating the secretion and release of insulin from pancreatic β-cells (pancreatic action). As with other sulfonylurea derivatives, this effect is based on an increase in the response of pancreatic β-cells to physiological stimulation with glucose, while the amount of secreted insulin is much less than with the action of traditional drugs — sulfonylurea derivatives. The least stimulating effect of glimepiride on insulin secretion also provides a lower risk of hypoglycemia. In addition to this, glimepiride has an extrapancreatic effect — the ability to improve the sensitivity of peripheral tissues (muscle, fat) to the action of its own insulin, reduce the absorption of insulin by the liver; inhibits the production of glucose in the liver. Glimepiride selectively inhibits cyclooxygenase and reduces the conversion of arachidonic acid to thromboxane A2, which promotes platelet aggregation, thus exerting an antithrombotic effect.

Glimepiride contributes to the normalization of lipid levels, reduces the level of malonic aldehyde in the blood, which leads to a significant decrease in lipid peroxidation, this contributes to the antiatherogenic effect of the drug.

Indications

Treatment of type 2 diabetes mellitus with the ineffectiveness of a previously prescribed diet and exercise.

If monotherapy with glimepiride is ineffective, it can be used in combination therapy with metformin or insulin.

Dosage and administration

The average initial dosage is 1-2 mg once a day during breakfast.

The maximum starting dosage is 2 mg.

Contraindications

-diabetes mellitus type 1;

— diabetic ketoacidosis,

— diabetic precoma and coma;

Side effects

From the side of metabolism: in rare cases, the development of hypoglycemic reactions is possible.

On the part of the organ of vision: during treatment (especially at its beginning), transient visual impairment may occur due to changes in the concentration of glucose in the blood.

From the digestive system: sometimes there may be nausea, vomiting, a feeling of heaviness or discomfort in the epigastrium.